Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells.
about
Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?Beyond the Niche: Myelodysplastic Syndrome Topobiology in the Laboratory and in the ClinicMurine xenogeneic models of myelodysplastic syndrome: an essential role for stroma cellsThe hematopoietic stem cell niche in homeostasis and diseaseManagement of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Myogenic differential methylation: diverse associations with chromatin structure.Myelodysplastic syndromes: diagnosis, prognosis, and treatment.Notch signaling in the malignant bone marrow microenvironment: implications for a niche-based model of oncogenesis.Feedback signals in myelodysplastic syndromes: increased self-renewal of the malignant clone suppresses normal hematopoiesis.Sonic hedgehog produced by bone marrow-derived mesenchymal stromal cells supports cell survival in myelodysplastic syndromeBiology of BM failure syndromes: role of microenvironment and niches.Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes.Endothelial progenitor cell dysfunction in myelodysplastic syndromes: possible contribution of a defective vascular niche to myelodysplasia.Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients.Notch-Hes pathway mediates the impaired osteogenic differentiation of bone marrow mesenchymal stromal cells from myelodysplastic syndromes patients through the down-regulation of Runx2.Defective proliferative potential of MSCs from pediatric myelodysplastic syndrome patients is associated with cell senescence.Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome.Down-regulation of Dicer1 promotes cellular senescence and decreases the differentiation and stem cell-supporting capacities of mesenchymal stromal cells in patients with myelodysplastic syndrome.Co-culture with podoplanin+ cells protects leukemic blast cells with leukemia-associated antigens in the tumor microenvironment.Enoxaparin and rivaroxaban have different effects on human mesenchymal stromal cells in the early stages of bone healingIdentity, proliferation capacity, genomic stability and novel senescence markers of mesenchymal stem cells isolated from low volume of human bone marrow.JAK2V617F-mutant megakaryocytes contribute to hematopoietic stem/progenitor cell expansion in a model of murine myeloproliferation.The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system.Downregulation of MMP1 in MDS-derived mesenchymal stromal cells reduces the capacity to restrict MDS cell proliferation.Mesenchymal stem cells in immune-mediated bone marrow failure syndromes.Regulation of hematopoiesis by activators and inhibitors of Wnt signaling from the niche.The inflammatory microenvironment in MDS.Age-related changes in natural killer cell repertoires: impact on NK cell function and immune surveillance.Impaired Expression of Focal Adhesion Kinase in Mesenchymal Stromal Cells from Low-Risk Myelodysplastic Syndrome Patients.The microenvironment in myelodysplastic syndromes: niche-mediated disease initiation and progression.Mesenchymal stromal cells contribute to quiescence of therapy resistant leukemic cells in acute myeloid leukemia.Preclinical modeling of myelodysplastic syndromes.Concise Review: The Malignant Hematopoietic Stem Cell Niche.Bone Marrow-Derived Mesenchymal Stromal Cells from Patients with Sickle Cell Disease Display Intact Functionality.CD44 standard and CD44v10 isoform expression on leukemia cells distinctly influences niche embedding of hematopoietic stem cellsMyeloid malignancies and the microenvironment.The aging hematopoietic stem cell niche: Phenotypic and functional changes and mechanisms that contribute to hematopoietic aging.Mesenchymal stromal cells in myeloid malignancies.Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.Role of Distinct Natural Killer Cell Subsets in Anticancer Response.
P2860
Q26746104-374B0CEB-638A-4FE9-9545-CA9AD0C93896Q26752778-A7E633E5-0901-4B58-AA6F-F959E166D216Q27023457-7B99D85F-D731-4C0A-BD25-34AAA31B6AD2Q28082775-9E04412A-BC55-4F6D-8ED4-007AF61590A1Q30235355-A90AFEBF-3884-4C18-AA7E-06CA78C54B71Q33858718-A72428B2-A8B1-4A4A-8552-79DE62C3B1A8Q34389508-50F190A9-EEBC-4586-BE94-1808DE26138FQ34898535-C77A6078-2103-4B6D-BF53-E4F867F37630Q35156907-FD6279FB-EE00-4C02-8FAD-A7A24FAF7879Q35227073-8C7020F8-D46D-41B5-92DC-9D1B625840B5Q35568527-05B5366B-E9A3-42E9-97A3-53174A2BEE6CQ35571031-828C7ED8-7C6D-4820-A5C2-5D168CBC5180Q35745087-0062AAA0-E0B4-4A71-9E78-0A84390F38E4Q35911998-376F4856-0EAA-44C3-84B8-A180C10D28A6Q36309518-4D33369B-1BC0-43A7-942D-B02D0966BD09Q36375313-9F7CCCF5-7ADC-4FAF-B7AC-36836BF98C7AQ36547805-1171A9DA-9884-45DB-8C1A-56B1C186B1B7Q36715982-D7C4DF1B-D89F-4E0B-B167-5D1EED2E5D1CQ36817324-383DEA30-AEEE-409A-B4BF-69935CC3F1FAQ36857020-C0B0E377-6EE6-4FB8-9968-E577B92E021AQ36998092-D1AD3781-F989-4DB3-A68F-BC471E9397AFQ37506624-3624DF9A-48D1-412A-91A3-2FCA5369236EQ37618945-09E32974-EDD9-4AF3-B211-2462E8DDAD35Q37682247-046C8714-7392-490F-AA23-D060725E22B0Q38175397-6B62056A-56FD-42F4-969E-8D5CFDE4774BQ38194615-E41C7F1F-356F-43B0-9EA9-3B93229F6859Q38348119-268050AA-9A45-406A-815A-976A71DC4227Q38569499-920A05B5-0154-4F27-884A-D68C97DA1E3CQ38604716-0E2E13AD-8918-4773-B4CB-C38EA092E9AFQ38615755-41BAB4F3-050B-420E-97A6-7C894538125EQ38628894-BB75E9AA-4C1D-4DEE-BFCF-784D6DA7CA29Q38701479-A7A9DEEA-FDED-41FA-AE96-613878844EB9Q38959361-F1AB0463-994D-4DBE-B775-F696D4074A9BQ38993061-F5C39A46-A586-42F5-9EDB-76F0EF60B5A1Q39010027-97C1C8FC-1CB5-4D82-A105-1648262DA9DBQ39073878-A037C2D1-006D-41B6-B1A9-A5F7E835A24EQ39089125-8330FC2A-91F5-419B-B804-3E414493FBA8Q39090002-ABACF682-78F5-4FFA-A0F6-4ECBE2813A7CQ39155501-D3119276-1CE8-467B-BE68-9E5D1DDFC97AQ39210022-2C6C9C81-8096-4094-B969-5E2952CDD63F
P2860
Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Insufficient stromal support i ...... of mesenchymal stromal cells.
@en
Insufficient stromal support i ...... of mesenchymal stromal cells.
@nl
type
label
Insufficient stromal support i ...... of mesenchymal stromal cells.
@en
Insufficient stromal support i ...... of mesenchymal stromal cells.
@nl
prefLabel
Insufficient stromal support i ...... of mesenchymal stromal cells.
@en
Insufficient stromal support i ...... of mesenchymal stromal cells.
@nl
P2093
P2860
P356
P1433
P1476
Insufficient stromal support i ...... of mesenchymal stromal cells.
@en
P2093
B Brückner
N Gattermann
P2860
P2888
P304
P356
10.1038/LEU.2013.193
P577
2013-03-29T00:00:00Z